89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

NACompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Glioblastoma
Interventions
DRUG

89Zr-J591

The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.

DEVICE

PET/CT Scan

DEVICE

MRI

OTHER

Blood draw

Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Weill Medical College of Cornell University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02410577 - 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter